Ocugen, Inc. 8-K

What Happened

• Ocugen, Inc. filed a Form 8-K reporting that on January 20, 2026 it entered into an underwriting agreement with Oppenheimer & Co. Inc. to sell 15,000,000 shares of common stock at $1.50 per share.
• The offering is expected to close on or about January 22, 2026, subject to customary closing conditions, and Ocugen issued a press release on January 21, 2026 announcing the pricing.

Key Details

• Offering size: 15,000,000 shares of common stock at $1.50 per share (gross proceeds $22,500,000).
• Expected net proceeds to Ocugen: approximately $20.8 million after underwriting discounts, commissions and estimated offering expenses.
• Use of proceeds: for general corporate purposes, capital expenditures, working capital and general and administrative expenses.
• Underwriter and legal: Underwriting agreement with Oppenheimer & Co. Inc.; legal opinion on the issuance delivered by Goodwin Procter LLP. Shares issued under the company’s previously effective Form S-3 registration.

Why It Matters

• The offering provides Ocugen with near-term capital (about $20.8M net) to fund operations and corporate needs, which can extend the company’s runway or support ongoing programs.
• Issuing 15 million new shares will dilute existing shareholders’ ownership; investors should consider potential dilution and consult Ocugen’s filings for effects on shares outstanding.
• The offering remains subject to customary closing conditions and the forward-looking statements in the 8-K caution that market conditions or other risks could affect completion or outcomes.